文献速递特殊人群用药药物不良反应与药物警戒

功能性IV级慢性血栓栓塞性肺动脉高压患者由静脉曲普前列素转为口服治疗的病例报告

Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
PubMed 文献 · Pharmacotherapy · 2017-06-30

本文报告一例42岁男性T12截瘫合并功能性IV级慢性血栓栓塞性肺动脉高压(CTEPH)及严重压力性溃疡患者,因需出院至无法给予肠外前列环素的专业护理机构,在6天内从静脉曲普前列素交叉转换为口服西乐葆(selexipag)。患者因症状恶化再入院并换回静脉曲普前列素,后耐受口服曲普前列素约4个月,但因恶心及治疗目标调整而停药,3个月后转入临终关怀并最终死亡。这是首例报道CTEPH患者从静脉曲普前列素转为西乐葆及从肠外转为口服曲普前列素。

要点

  • CTEPH患者从静脉曲普前列素快速交叉转换为口服西乐葆(6天)后因症状恶化再入院。
  • 口服曲普前列素耐受约4个月,因恶心及治疗目标调整停药。
  • 前列腺素转换需密切监测疗效与耐受性,尤其复杂共病患者。

核心结论

  • 首例报道CTEPH患者从静脉曲普前列素转为口服西乐葆及从肠外转为口服曲普前列素,提示前列腺素转换存在潜在问题。

研究设计与样本

  • 病例报告:42岁男性T12截瘫合并功能性IV级CTEPH、严重右心室功能障碍及严重压力性溃疡。

主要发现

  • 6天交叉转换为口服西乐葆后因症状恶化再入院并换回静脉曲普前列素。
  • 耐受口服曲普前列素约4个月,因恶心及治疗目标调整停药。
  • 3个月后转入临终关怀并最终死于临床恶化。

关键数值与推荐

  • CTEPH无法手术或残留时,利奥西呱是美国FDA唯一批准的治疗。
  • 部分CTEPH患者可能需要利奥西呱以外的治疗,如静脉前列环素。

临床怎么用

  • 复杂共病患者需考虑前列腺素转换以促进出院至护理机构,但应警惕症状恶化。
  • 转换后需监测疗效与耐受性,口服曲普前列素可能因恶心停药。

局限性

  • 单例病例报告,结论需更多观察以比较西乐葆与口服曲普前列素的疗效和耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic thromboembolic pulmonary hypertension (CTEPH) occurs when pulmonary emboli fail to resolve with anticoagulation. For patients with inoperable or residual CTEPH, riociguat is currently the only therapy approved by the United States Food and Drug Administration. However, some patients with CTEPH may require therapy beyond riociguat, such as intravenous prostacyclins, which can present significant administration challenges in patients with complex comorbid conditions. We describe a 42-year-old man with T12 paraplegia complicated by CTEPH (functional class IV with substantial right ventricular dysfunction) and severe pressure ulcers. In order to facilitate goals of care (hospital discharge to a skilled nursing facility where parenteral prostanoids could not be administered), he underwent rapid transition from intravenous treprostinil to oral selexipag in the form of a cross-taper over 6 days. The patient required readmission due to worsening symptoms and was transitioned back to intravenous treprostinil; he tolerated conversion to oral treprostinil for approximately 4 months, but it was subsequently discontinued due to nausea and modified goals of care. The patient underwent transition to hospice care 3 months later and eventually died from clinical deterioration. To our knowledge, this is the first report to describe transition from intravenous treprostinil to selexipag as well as conversion from parenteral treprostinil to oral treprostinil in a patient with CTEPH and illustrates the approaches to and potential issues with prostanoid transitions. Additional observations are necessary to better understand the relative roles of selexipag and oral treprostinil regarding comparative efficacy and tolerability.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Thurber KM, Williams BM, Bates RE, et al. Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension. Pharmacotherapy. 2017. PMID: 28513869. doi:10.1002/phar.1951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。